Agilon Health (NYSE:AGL) Stock Price Up 4.4% – Here’s Why

Agilon Health, Inc. (NYSE:AGL)’s share price was up 4.4% during trading on Friday. The stock traded as high as $78.24 and last traded at $79.1680. Approximately 15,002 shares were traded during trading, a decline of 96% from the average session volume of 335,667 shares. The stock had previously closed at $75.83.

Analyst Upgrades and Downgrades

AGL has been the subject of a number of analyst reports. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $146.00 price target (up from $141.00) on shares of Agilon Health in a research report on Tuesday, August 11th. Benchmark reissued a “buy” rating and set a $140.00 price objective (up from $95.00) on shares of Agilon Health in a report on Thursday, August 6th. Robert W. Baird set a $116.00 price objective on Agilon Health in a research note on Thursday, August 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a report on Monday, August 24th. Finally, JPMorgan Chase & Co. upped their target price on Agilon Health from $31.00 to $85.00 and gave the stock an “underweight” rating in a research report on Monday, August 24th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $102.25.

Agilon Health Trading Up 10.6%

The business has a fifty day moving average price of $94.72 and a 200 day moving average price of $74.10. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -5.86 and a beta of 3.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.08 and a quick ratio of 1.08.

Agilon Health (NYSE:AGL) last released its earnings results on Wednesday, August 5th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $0.14 by $0.90. The firm had revenue of $1.49 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Agilon Health had a negative net margin of 3.92% and a negative return on equity of 119.38%. On average, equities analysts expect that Agilon Health, Inc. will post -2.9 EPS for the current fiscal year.

Institutional Trading of Agilon Health

A number of hedge funds have recently modified their holdings of AGL. State Street Corp bought a new position in Agilon Health in the second quarter worth $30,024,000. North Peak Capital Management LLC raised its stake in shares of Agilon Health by 10.8% in the 4th quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company’s stock valued at $26,267,000 after buying an additional 3,715,460 shares in the last quarter. Rubicon Founders LLC bought a new position in shares of Agilon Health during the 2nd quarter worth about $11,290,448. Bank of New York Mellon Corp boosted its position in shares of Agilon Health by 9.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 35,336 shares of the company’s stock valued at $3,787,000 after acquiring an additional 3,074 shares in the last quarter. Finally, UBS Group AG boosted its position in shares of Agilon Health by 250.7% during the 4th quarter. UBS Group AG now owns 3,395,366 shares of the company’s stock valued at $2,339,000 after acquiring an additional 2,427,136 shares in the last quarter.

About Agilon Health

Agilon Health, Inc is a healthcare company that partners with independent primary care physicians to support the transition from fee-for-service medicine to value-based care. The company focuses primarily on patients enrolled in Medicare Advantage plans and works with physician groups to coordinate care, improve outcomes and manage healthcare costs.

Agilon provides physicians with technology, analytics, operational support and clinical resources designed to help them manage the health of defined patient populations.